|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-1
|
|
pubmed:abstractText |
The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. GSTP1 Ile(105)Val polymorphism was detected by TaqMan-MGB probe allelic discrimination method. Response to treatment was assessed by disease controlled rate. Time to progression, overall survival and toxicities were recorded. Final patient outcomes were as follows: the allele frequencies of GSTP1 were (105)Ile/(105)Ile 52%, (105)Ile/(105)Val 41% and (105)Val/(105)Val 7%. For patients with (105)Ile/(105)Ile and those with at least one (105)Val allele, disease control rate was 39% and 71% (P=0.026), respectively; median time to progression was 4.0 and 7.0 months (P=0.002); median overall survival time was 7.0 and 9.5 months (P=0.002). Neurological toxicity was more frequently occurred in patients with two (105)Ile alleles (P=0.005). In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-10334868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-10630679,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-10894863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-11477586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-12072547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-12360105,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-12525681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-14710198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-15213713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-15729594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-15928658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16002846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16166979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16317430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16707601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16765644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-16957145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-17075117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-17147808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-17409936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-17593927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-18221042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-18443805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-19223573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-2348469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-9498276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20514304-9609103
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1598-6357
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
846-52
|
|
pubmed:dateRevised |
2010-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20514304-Adult,
pubmed-meshheading:20514304-Aged,
pubmed-meshheading:20514304-Alleles,
pubmed-meshheading:20514304-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20514304-Disease Progression,
pubmed-meshheading:20514304-Female,
pubmed-meshheading:20514304-Fluorouracil,
pubmed-meshheading:20514304-Gene Frequency,
pubmed-meshheading:20514304-Genotype,
pubmed-meshheading:20514304-Glutathione S-Transferase pi,
pubmed-meshheading:20514304-Humans,
pubmed-meshheading:20514304-Male,
pubmed-meshheading:20514304-Middle Aged,
pubmed-meshheading:20514304-Organoplatinum Compounds,
pubmed-meshheading:20514304-Polymorphism, Single Nucleotide,
pubmed-meshheading:20514304-Stomach Neoplasms,
pubmed-meshheading:20514304-Survival Analysis,
pubmed-meshheading:20514304-Time Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
|
|
pubmed:affiliation |
Treatment and Research Center of Oncology, The Affiliated Hospital of Medical College of Qingdao University, Qingdao, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
